Background Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma
Summary
Background Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patientreported outcomes (PROs).
Methods CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progressed within 6 months after platinum-based chemotherapy. Patients were randomly assigned (2:1) to nivolumab 3 mg/kg every 2 weeks (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/m² of body surface area), docetaxel (30-40 mg/m²), or cetuximab (250 mg/m² after a loading dose of 400 mg/m²) until disease progression, intolerable toxicity, or withdrawal of consent. On Jan 26, 2016, the independent data monitoring committee reviewed the data at the planned interim analysis and declared overall survival superiority for nivolumab over investigator's choice therapy (primary endpoint; described previously). The protocol was amended to allow patients in the investigator's choice group to cross over to nivolumab. All patients not on active therapy are being followed for survival. As an exploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35), and the three-level European Quality of Life-5 Dimensions (EQ-5D) questionnaire. Differences within and between treatment groups in PROs were analysed by ANCOVA among patients with baseline and at least one other assessment. All randomised patients were included in the time to clinically meaningful deterioration analyses. Median time to clinically meaningful deterioration was analysed by Kaplan-Meier methods. CheckMate 141 was registered with ClinicalTrials.org, number
NCT02105636.
Findings Patients were enrolled between May 29, 2014, and July 31, 2015, and subsequently 361 patients were randomly assigned to receive nivolumab (n=240) or investigator's choice (n=121). Among them, 129 patients (93 in the nivolumab group and 36 in the investigator's choice group) completed any of the PRO questionnaires at baseline and at least one other assessment. Treatment with nivolumab resulted in adjusted mean changes from baseline to week 15 ranging from −2·1 to 5·4 across functional and symptom domains measured by the EORTC QLQ-C30, with no domains indicating clinically meaningful deterioration. By contrast, eight (53%) of the 15 domains in the investigator's choice group showed clinically meaningful deterioration (10 points or more) at week 15 (change from baseline range, −24·5 to 2·4).
Similarly, on the EORTC QLQ-H&N35, clinically meaningful worsening at week 15 was seen in no domains in the nivolumab group and eight (44%) of 18 domains in the investigator's choice group. Patients in the nivolumab group had a clinically meaningful improvement (according to a difference of 7 points or greater) in adjusted mean change from baseline to week 15 on the EQ-5D visual analogue scale, in contrast to a clinically meaningful deterioration in the investigator's choice group (7·3 vs −7·8). Differences between groups were significant and clinically meaningful at weeks 9 and 15 in favour of nivolumab for role functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pain and sensory problems on the EORTC QLQ-H&N35. Median time to deterioration was significantly longer with nivolumab versus investigator's choice for 13 (37%) of 35 domains assessed across the three questionnaires.
Interpretation In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms and functioning from baseline to weeks 9 and 15, whereas investigator's choice led to clinically meaningful deterioration. Nivolumab delayed time to deterioration of patient-reported quality-of-life outcomes compared with single-agent therapy of investigator's choice in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in this population and the importance of maintaining or improving quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivolumab as a new standard-of-care option in this setting.
Funding Bristol-Myers Squibb.
Research in context Evidence before this study
We searched prospective clinical trial publications indexed in PubMed during the past 10 years (Dec 1, 2006, to Dec 1, 2016) for the title or abstract terms "head and neck" and "carcinoma" or "cancer" and "quality of life" and "recurrent", or "metastatic". The search returned 15 publications, most of which used chemotherapy-based combinations. Among platinumrefractory patients, no treatment was noted as having significant improvements on quality of life.
The search returned only one report on quality of life in a trial investigating the use of a checkpoint inhibitor for squamous cell carcinoma of the head and neck: the phase 3 CheckMate 141 study, which compared nivolumab with single-agent therapy of investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In CheckMate 141, overall survival was significantly longer for patients treated with nivolumab than for those treated with investigator's choice. Grade 3 or 4 treatment-related adverse events were less frequent with nivolumab versus investigator's choice. The study reported that mean changes from baseline in patient-reported outcome (PRO) domains assessed on the European 
Added value of this study
Our study provides complete CheckMate 141 patient-reported quality of life analyses for the overall population and subgroups of clinical interest. To our knowledge, this is the first study showing PROs from a clinical trial assessing a checkpoint inhibitor antibody in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients treated with nivolumab maintained baseline levels of quality of life, as assessed by three validated PRO measures. By contrast, investigator's choice led to clinically meaningful deteriorations.
Nivolumab treatment led to a significant delay in deterioration across a number of quality of life domains compared with investigator's choice.
Implications of all the available evidence
Combined with the primary report from CheckMate 141, results from this study indicate that treatment with nivolumab offers a new therapeutic approach to extend survival that might also preserve or enhance quality of life in patients with advanced squamous cell carcinoma of the head and neck.
Introduction
Squamous cell carcinoma of the head and neck, including cancers of the oral cavity, pharynx, and larynx, and its treatment have a major effect on patient quality of life. 1 Damage to anatomic structures involved in speech, swallowing, and breathing can be caused by the tumour itself or can occur as the result of surgical resection, chemoradiotherapy, or both. 2 Consequently, changes to basic physical functions, physical appearance, and social interactions are common among patients with squamous cell carcinoma of the head and neck. 3 Patients with squamous cell carcinoma of the head and neck have been shown to bear greater psychological distress than those patients with many other cancer types because of treatment-related facial disfigurement or impaired speech, breathing, eating, or drinking. 4 In addition to negative effects on quality of life, patients with recurrent or metastatic squamous cell carcinoma of the head and neck have a dismal prognosis. Median overall survival for patients who progress after platinum therapy for primary or recurrent disease is 6 months or less. 5, 6 Patient-reported outcomes (PROs) have been collected to assess quality of life in a small number of clinical trials of chemotherapy and targeted therapies in recurrent or metastatic squamous cell carcinoma of the head and neck, few of which have shown improvements or significant differences between treatment groups. 7-10 However, baseline quality of life scores have been reported to be independent prognostic factors for overall survival in patients with recurrent or metastatic head and neck cancer. 11 Therefore, there is a large unmet medical need for treatments that improve prognosis as well as preserve and maximise quality of life.
Because squamous cell carcinoma of the head and neck recurrence and metastasis are enabled by tumour immune evasion, mediated in part by the T cell-suppressive programmed death (PD)-1 immune checkpoint, PD-1 inhibitors are of clinical interest in this setting.
Nivolumab is a fully human IgG4 PD-1 inhibitor antibody that disrupts PD-1-mediated signalling Nivolumab was provided by the sponsor (Bristol-Myers Squibb, Princeton, NJ, USA).
On Jan 26, 2016, the independent data monitoring committee reviewed the data at the planned interim analysis and declared overall survival superiority for nivolumab over investigator's choice therapy. 16 The protocol was amended to allow patients in the investigator's choice group to cross over to nivolumab. All patients not on active therapy are being followed for survival.
Randomisation and masking
Patients were randomly assigned Disease assessments were done with CT or MRI at baseline, and every 6 weeks beginning at week 9. Imaging data were assessed by the investigators to establish tumour response according to RECIST version 1.1. Toxicity was assessed according to Common
Terminology Criteria for Adverse Events version 4.0 at each visit during the treatment phase and for 100 days after discontinuation. Patients were followed for overall survival every 3 months until death, loss to follow-up, or withdrawal of consent.
Formalin-fixed, paraffin-embedded tumour samples required for enrolment were centrally assessed for tumour-cell membrane expression of programmed death ligand 1 (PD-L1) by immunohistochemistry (Dako North America, Carpinteria, CA, USA) using a rabbit antihuman PD-L1 antibody (clone 28-8, Epitomics, Burlingame, CA, USA). Expression in a minimum of 100 evaluable tumour cells was scored for PD-L1 (≥1% or <1% expression).
Documentation of p16-positive or p16-negative disease to determine human papillomavirus (HPV) status of tumour was required for patients with oropharyngeal cancer.
HPV p16 status was assessed by local or central laboratory immunohistochemical analysis.
Samples were considered positive if more than 70% strong and diffuse nuclear and cytoplasmic staining specific to tumour cells was present.
PRO assessments were done at baseline before treatment initiation, at week 9, and then every 6 weeks during the treatment period using three validated patient-reported Dimensions (EQ-5D-3L) questionnaire. Post-treatment assessments were made at follow-up visits 1 and 2 (35 days give or take 7 days after the last treatment dose, and 80 days give or take 7 days after follow-up visit 1). The EQ-5D-3L questionnaire was also administered at survival follow-up visits (every 3 months give or take 7 days after follow-up visit 2). Patients completed their assessments at each timepoint before physician contact, treatment dosing, or any procedures. PRO measures were self-administered by paper and pencil during the ontreatment phase and at follow-up visits 1 and 2. They were either self-administered by paper and pencil or completed via a telephone interview during survival follow-up. Specific information about reasons patients did not complete questionnaires were not collected, because this was not specified in the protocol.
The EORTC QLQ-C30 questionnaire (version 3.0) consists of five functional scales (physical, role, social, emotional, and cognitive functioning), nine scales measuring symptoms or concerns relevant to patients with cancer (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), as well as one scale measuring global health and quality of life. 23, 24 For each functional and symptom question, patients responded to a 4-point categorical scale ranging from 1 ("not at all") to 4 ("very much");
responses to the two items in the global health and quality-of-life scale were given on a 7-point Likert scale. Item responses were aggregated and linearly transformed to a 0-100 scale according to the EORTC scoring manual. 25 From there, scales where higher scores represented higher symptom burden were reverse-scored to simplify presentation within this report so that for all scales a higher score represents better quality of life.
The EORTC QLQ-H&N35 questionnaire consists of seven multi-item symptom scales (pain, sensory problems, social contact problems, swallowing, social eating problems, speech problems, and reduced sexuality) and 11 single-item symptom scales (nutritional supplement use, mouth opening problems, teeth problems, coughing, painkiller use, weight loss, weight gain, sticky saliva, feeding tube, dry mouth, and feeling ill). 26, 27 Most items were rated on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"); five components used a binary response set ("yes" or "no"). Patient responses were transformed to a 0-100 scale according to the EORTC scoring manual. 25 From there, scales were reverse-scored to simplify presentation within this report so that for all scales a higher score represents better quality of life.
The EQ-5D-3L is a standardised questionnaire commonly used to measure self-reports of health status and functioning. 28,29 It consists of two components, a descriptive system and a visual analogue scale (VAS). The descriptive system covers five dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), each of which is rated on a three-level scale (corresponding roughly to no problems, moderate problems, or extreme problems), resulting in a five-digit vector that describes a patient's health state-eg, vectors 11111 and 33333 represent the best and worst health states possible, respectively. EQ-5D
responses were weighted and aggregated using the UK preference-weighting algorithm 30 to produce utility scores measuring the value of a respondent's health state to society, where a score of 0 was equivalent to being dead and 1 was equivalent to full health. The VAS is a vertical scale from 0 (worst imaginable) to 100 (best imaginable), on which patients were asked to report their overall health status on that day.
Outcomes
The primary endpoint of CheckMate 141 was overall survival, defined as time from randomisation to the date of death, reported previously. 16 Secondary endpoints were investigator-assessed progression-free survival and the proportion of participants who achieved an objective response per RECIST version 1.1. PRO analyses were exploratory endpoints. PRO endpoints were interpreted based upon both significant differences and clinically meaningful differences. Statistical differences in PRO endpoints included evaluation of adjusted mean changes from baseline between treatment groups as assessed by the EORTC QLQ-C30, EORTC QLQ-H&N35, and EQ-5D-3L at each timepoint, and the time to clinically meaningful deterioration per each individual scale's criteria.
The clinically meaningful difference, indicating a change that would be detectable by patients and might mandate a change in the patient's management, was a score difference of 10 points or more for all domains on both EORTC questionnaires. 31 Interpretation for the EORTC QLQ-C30 was also prespecified based on newer subscale-specific guidelines, where clinically meaningful score differences vary by domain. 32, 33 A change from baseline of 10 points was also used as a clinically important deterioration within an individual for the time to deterioration analyses for all domains on both EORTC questionnaires. Score differences of 0·08 or more for the EQ-5D utility index and 7 or more for the EQ-5D VAS have been determined to be clinically relevant and were used as the clinically meaningful difference for these measures.
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Statistical analyses
The statistical analysis of the exploratory PRO endpoint were predefined in a PRO statistical analysis plan. Assessments were considered complete if at least half of the questions were completed or answered. Completion rates were calculated for each PRO measure as the proportion of patients alive in the study at the assessment timepoint with a completed questionnaire. To investigate the relation of PRO scores with dropout, patients were grouped according to the timing of their last assessment and mean PRO scores plotted over time for each group by treatment group. Patients with dropout after 21 weeks were combined because of small sample sizes.
Quality of life results within and between treatment groups were assessed using descriptive statistics and ANCOVA, adjusted for the stratified randomisation (previous cetuximab therapy) and baseline score, at each timepoint when sample size was 10 or more.
The ANCOVA model treated change from baseline as the dependent variable and treatment and visit as fixed effects, with visits as a repeated measure. A separate analysis was done for each domain, and only patients with questionnaires completed at baseline and at least one post-baseline assessment were included in the analysis. Missing data were not imputed. Median time from randomisation to first deterioration (defined based on clinically meaningful change) was estimated by the Kaplan-Meier method, and two-sided 95% CIs were computed using a generalisation of the Brookmeyer and Crowley method (log-log transformation). Deterioration was applied at the individual patient level; confirmation was not required at a subsequent visit; progression or death were not included as events or censored. A
Cox proportional hazard regression model was used to estimate relative risk for the time to deterioration, treating baseline score and previous cetuximab therapy as covariates. Hazard ratios (HRs) were calculated for the risk of deterioration in the nivolumab group over the investigator's choice group, with ratios less than 1 representing decreased likelihood of experiencing deterioration in the nivolumab group. All randomised patients were included in the time-to-deterioration analyses; these analyses include data collected at all available timepoints, including post-treatment follow-up. Patients with no baseline PRO data were censored to day 1; patients with baseline but no additional post-baseline data were censored to day 2. 34 This censoring was necessary because Cox hazard ratio estimates can only be calculated on cases with non-missing baseline covariates.
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The data cutoff point for the analyses of overall survival, progression-free survival, and safety was Dec 18, 2015 (planned interim analysis). Response and PRO data were based on a May 5, 2016, database lock.
Data were analysed with SAS (version 9.4, SAS Institute, Cary, NC, USA).
This trial is registered with ClinicalTrials.gov, number NCT02105636.
Role of the funding source
The funders contributed to the study design, and the collection, analysis, and interpretation of the data in collaboration with the investigators and authors of this report. Funds for editorial and writing support were provided by the funder. All authors had full access to the raw data. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results
Between May 29, 2014, and July 31, 2015, patients were enrolled, and subsequently 361 patients were randomly assigned to receive nivolumab (n=240) or investigator's choice (n=121). At both weeks 9 and 15, adjusted mean differences between groups were significant and clinically meaningful (according to a difference of 10 points or greater) in favour of nivolumab for role functioning, social functioning, fatigue, dyspnoea, and appetite loss (figure 1B). Additional significant and clinically meaningful differences favouring nivolumab were noted at either week 9
(diarrhoea) or week 15 (physical functioning, cognitive functioning, and insomnia). Further domains that were either significant or clinically meaningful are shown in figure 1B . No significant or clinically meaningful differences were noted in favour of investigator's choice on the EORTC QLQ-C30.
In exploratory analyses, we assessed changes from baseline in EORTC QLQ-C30 scores among patients whose tumours had 1% or more or less than 1% PD-L1 expression (appendix p 7) or were p16-positive or p16-negative (appendix p 8). Adjusted mean differences between treatment groups were in line with the overall treatment effect for each domain, suggesting no evidence of a differential benefit across these subgroups. appendix pp 5, 6). Changes from baseline in weight gain in the nivolumab group were −13·2 at week 9 and −15·2 at week 15, indicating that patients experienced an increase in weight at these timepoints. By contrast, treatment with investigator's choice led to clinically meaningful deterioration (decline of 10 points or more) at week 15 for sensory problems, social eating problems, social contact problems, mouth opening problems, sticky saliva, feeling ill, painkiller use, and weight loss (appendix pp 5, 6). The adjusted mean changes from baseline to weeks 9 and 15 for the investigator's choice group ranged from −26·8 to 13·4.
At weeks 9 and 15, adjusted mean differences between groups were significant and clinically meaningful (according to a difference of 10 points or greater) in favour of nivolumab for pain and sensory problems ( figure 3B ). Additional significant and clinically meaningful differences favouring nivolumab were noted at either week 9 (nutritional supplement use) or The EQ-5D VAS, a measure of the patient's overall health status, was similar between groups at baseline for the analytical cohort (n=124; appendix pp 5, 6) and all-randomised population (see supplementary table 7 in Ferris et al   16 ). However, patients in the nivolumab group had a clinically meaningful improvement (according to a difference of 7 points or greater)
in adjusted mean change in VAS score from baseline to week 15, by contrast with a clinically meaningful deterioration in the investigator's choice group (7·3 vs -7·8; appendix pp 5, 6).
Notably, the difference between groups at week 15 was both significant and clinically meaningful in favour of nivolumab ( figure 4A ). Median time to deterioration on the EQ-5D VAS was not significantly different ( figure 4B, 4C ).
Baseline utility index score, a composite score representing the value placed by society on a respondent's current health state as defined based on the attributes measured by the EQ-5D, was similar in the two treatment groups (appendix pp 5, 6). Neither significant nor clinically meaningful differences in outcomes were observed at 9 or 15 weeks within or between groups (figure 4A). Median time to deterioration on the EQ-5D utility index was not significant (figure 4B, 4C). Median time to deterioration was significantly longer with nivolumab versus investigator's choice for 13 (37%) of 35 domains assessed across the three questionnaires.
Discussion
Here we report that nivolumab stabilised several measures of quality of life during the first 15 weeks of treatment of patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck, and delayed time to deterioration compared with singleagent therapy of investigator's choice based on an exploratory analysis from CheckMate 141, a randomised, phase 3 trial. The clinical benefit, as measured by these validated PRO measures, indicates that patients experienced improved quality of life in addition to prolonged survival, higher response rate, and fewer high-grade toxicities relative to investigator's choice. 16 These results are consistent with studies of nivolumab in melanoma, non-small-cell lung cancer, and renal cell carcinoma, which showed stable or improved quality of life with nivolumab compared with dacarbazine, docetaxel, and everolimus, respectively. [35] [36] [37] [38] Maximising the quality of life of patients with cancer is increasingly recognised as an important therapeutic goal, 1,10 particularly in the context of improved survival. Patients with squamous cell carcinoma of the head and neck rank the ability to speak, swallow, and perform daily tasks in the absence of pain as very high priorities. 39 In our analyses, the endpoint predefined in the statistical analysis plan was time to quality-of-life deterioration, which does not include death as an event. No consensus exists on the best definition to use for time to deterioration analyses; however, our analysis followed current recommendations. 34 Importantly, the threshold used to determine clinical relevance on the EORTC QLQ-C30 (10 points) is based on observations in other cancers. Based on a recent meta-analysis from Cocks and colleagues 32,33 consisting of multiple cancers and a variety of clinical situations, clinically meaningful differences might in fact be seen at even lower thresholds. Therefore, the use of a 10-point difference in our manuscript is probably a conservative estimate of within and between-treatment group differences. With the newer guidelines, additional domains showed improvement with nivolumab or deterioration with investigator's choice, indicating that the overall clinical benefit of nivolumab might be even greater.
To our knowledge, this is the first comprehensive report on PROs for an immunotherapy agent in squamous cell carcinoma of the head and neck. Furthermore, few studies have reported on the quality of life, symptom burden, or functioning in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 1, 7, 10 In the EXTREME study, Furthermore, the EQ-5D is a measure that can be used in general or targeted clinical populations, and is not apt to be as sensitive as a condition-targeted measure that is used in the designated population. However, the EQ-5D includes other measures that are important to patients with squamous cell carcinoma of the head and neck such as anxiety and depression, as well as measures not covered by the EORTC measures such as the ability to do general, daily activities.
No adjustment for multiple testing for exploratory endpoints is a common and widely accepted statistical practice. However, this could also be a limitation of the study in that an absence of alpha hierarchy and failing to adjust for multiplicity could have some implications for inferences that are close to the 0·05 benchmark. As is common with PROs, 8,10,19 our analysis was also limited by relatively low completion rates. After week 15, numbers in the investigator's choice group were so few as to preclude statistical comparisons between groups. Questionnaire response rates typically correspond to patient morbidity and functional status; patients affected by physical and psychological factors such as fatigue and depression might be unable to complete the assessments, depending on the response format, delivery, and length of the questionnaire. 1, 7, 42 One possible explanation for the higher level of missing data in the investigator's choice group is the potential bias of an open-label study, where the patient's excitement about the investigational agent might lead to more enthusiastic participation, including completion of questionnaires or ranking the agent positively. To explore the effect of patients being aware of their treatment allocation, baseline quality-of-life scores were compared across groups to determine whether there was a consistent bias. Across the 15 EORTC QLQ-C30 domains and 18 EORTC QLQ-H&N35 domains, only five domains had differences across the groups-worse financial difficulties, social eating, teeth problems, and dry mouth in the investigator's choice group, and increased painkiller use in the nivolumab group. Some of these differences might be expected by chance across this large number of domains, and this does not seem to imply a consistent bias in the quality-of-life responses towards the nivolumab group.
Baseline scores were accounted for in the ANCOVA analyses. This might also have been affected by differential progression or the higher number of patients experiencing prolonged disease control in the nivolumab group, whereby patients could have maintained the ability to respond to their questionnaires, as well as maintaining their quality of life. Another possible explanation is the known acute toxicity associated with therapies used in the investigator's choice group. Similar attrition has been noted in previous studies in patients with squamous cell carcinoma of the head and neck, with those discontinuing generally representing patients with the worst quality of life, 8, 20, 43 and presenting a significant challenge for statistical analyses. For example, during the EXTREME trial, 8 only 44% of patients had both an evaluable baseline and a post-baseline assessment. The nature of the missing data was investigated to understand the effect on results presented. The analysis population was similar to the full study population in terms of most demographics and disease characteristics. Generally, patients with only a baseline assessment had lower functioning and worse symptom scores than those providing further quality-of-life assessments. Before dropout, EORTC domain scores were stable in the nivolumab group but declined in the investigator's choice group. This would suggest that our estimates of treatment differences are likely to be conservative.
The results of CheckMate 141 suggest that nivolumab is the first PD-1 inhibitor, to our knowledge, to show a significant improvement in overall survival, with better tolerability and a quality-of-life benefit, compared with standard therapy for platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in this population and the importance of maintaining or improving quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivolumab as a new standard of care option in this setting.
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